Result of AGM

RNS Number : 1791Z
Alliance Pharma PLC
19 May 2021
 

For immediate release

19 May 2021

 

 

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")


Result of AGM

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, at its Annual General Meeting held earlier today, all the resolutions, as set out in the Notice of Meeting, were duly passed on a poll.

 

The votes were as follows:

 

RESOLUTION

VOTES FOR

%

VOTES AGAINST

%

VOTES TOTAL

% OF ISC VOTED

VOTES WITHHELD

1

Report and Accounts

370,082,283

99.99

2,000

0.01

370,084,283

69.20

365,173










2

Final dividend

370,448,446

100.00

0

0.00

370,448,446

69.27

1,010










3

Re-elect D. Cook

364,919,306

98.52

5,491,119

1.48

370,410,425

69.26

39,031










4

Re-elect P. Butterfield

369,183,937

99.67

1,229,509

0.33

370,413,446

69.26

36,010










5

Re-elect A. Franklin

368,811,050

99.57

1,602,396

0.43

370,413,446

69.26

36,010










6

Re-elect J. LeCouilliard

369,062,346

99.64

1,351,100

0.36

370,413,446

69.26

36,010










7

Re-elect R. Jones

369,069,846

99.64

1,340,579

0.36

370,410,425

69.26

39,031










8

Re-appoint Auditor

370,335,621

99.98

82,835

0.02

370,418,456

69.26

31,000










9

Remuneration of Auditor

370,375,357

99.99

43,099

0.01

370,418,456

69.26

31,00










10

Allot shares

322,454,915

87.05

47,976,358

12.95

370,431,273

69.26

18,183










11

Disapply Pre-emption rights

310,764,742

83.89

59,666,531

16.11

370,431,273

 

69.26

18,183

The number of the Group's shares in issue as at the date of the meeting was 534,827,034 ordinary shares of 1p each.

Please note that each share carries one vote and that a 'vote withheld' is not a vote in law and has not been counted in the calculation of the proportion of the votes for and against the resolution. Any proxy appointments which gave discretion to the Chairman have been included in the 'votes for' total.

Chris Chrysanthou
Head of Legal & Company Secretary
19 May 2021

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer


Andrew Franklin, Chief Financial Officer


www.alliancepharma.co.uk


Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff




Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Oliver Steele


Corporate Broking: James Black


 

Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams


Corporate Broking: Patrick Robb


 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGDKCBPBBKDQPD
UK 100